RankAlpha logo
Back to Rankings

TPST

Tempest TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Company-reported TPST-2003 data remain the core bull story: 100% CR among 15 CAR-T-naive efficacy-evaluable patients across REDEEM-1/POEMS-1, no Grade >=3 CRS or ICANS in REDEEM-1, and the AGCTC manufacturing setup keeps the planned U.S. registrational study on track [#SEC-8K-2026-05-14].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Dilution and price overhang from recent and potential warrant-linked financing.
Momentum
85
Value
41
Sentiment
76
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.45 · Bull $2.80 · Bear $0.60
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-03 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $11.00
Why
Momentum85 · Δ7d -
Value41 · Δ7d +0.1
Sentiment76 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
85
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
76
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 85.3 / Value 41.1 / Sentiment 75.6

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$21.47M
Beta
-2.45
Shares Out
4.93M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.48
Rev YoY
-
EPS YoY
+85.1%
Gross Margin
-
Op Margin
-
Net Debt
-$23.91M
Current Ratio
2.30
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology